Unbelievable, a well thought out, unbiased article. I always thought SA were short companies like this. I'm stunned. If you ignore the author's 2012 revenue mistake which claims $3.9 Billion in revenue, I believe this is, outside of Patrick Cox, the most accurate portrayal of the company that I've read yet.
"Overall, the likelihood of success of stem cell therapies is yet to be determined, but the current level of information certainly suggests that there is a great deal of promise in them. BioTime is not only focused on marketing therapies, but also increasing the research done in the field of stem cells. This would help in speedier education and acceptance of the stem cell therapies by people as they hear and learn more about the field. In my opinion, this company has the potential to become a long-term winner and should be within any biotech investor's radar"
Long time no see. Trust you have been well and prosperous. The general tendency to objectivity at SA (in comparison with yhoo posters) causes yhoo pumpers to scream that it shills for shorts so much it has become an urban legend. "Alpha" is merely the degree to which a position beats the random walk of indexes, and beta is how much the position varies from said walk.
On anther hand, anyone scummy enough to short who sees a pop on Monday from that SA article and can find the borrow will hit it, since, containing NO correct numbers, is not "accurate" at all.
.....Except in the comments.